0000926617 EX-FILING FEES ASPIRA WOMEN'S HEALTH INC. 0000926617 2025-09-30 2025-09-30 0000926617 1 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

Exhibit 107

 

Calculation of Filing Fee Table

 

FORM S-1

(Form Type)

 

ASPIRA WOMEN’S HEALTH INC.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

   Security Type  Security Class Title  Fee Calculation Rate   Amount Registered(1)   Proposed Maximum Offering Price Per Unit   Maximum Aggregate Offering Price (1)   Fee Rate   Amount of Registration Fee 
                       
Fees to be paid  Equity  Common Stock, par value
$0.001 per share
   457(c)    29,226,527   $.47(2)  $13,736,467.69    0.00015310   $2,103.06 
Fees previously paid                                    
                                     
      Total Offering Amount         $13,736,467.69        $2,103.06 
      Total Fees Previously Paid                    - 
      Total Fee Offsets                    - 
      Net Fee Due                   $2,103.06 

 

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover an indeterminate number of shares of common stock, par value $0.001 per share (the “Common Stock”) of Aspira Women’s Health Inc. (the “Company”) that may be issued and resold resulting from stock splits, stock dividends or similar transactions. Represents shares of Common Stock that may be offered for resale (the “Resale Shares”) by the selling stockholders described in this prospectus and are comprised of: (i) 5,915,850 shares of Common Stock issued in connection with the conversion of the Convertible Notes, (ii) 11,848,177 shares of Common Stock underlying the warrants underlying the Convertible Notes (as amended, the “Amended and Restated March 2025 Warrants”), (iii) 6,550,000 shares of Common Stock issued pursuant to the securities purchase agreement dated September 16, 2025 (the “September 2025 Purchase Agreement”), and (iv) 4,912,500 shares of Common Stock underlying warrants issued in connection with the September 2025 Purchase Agreement (the “September 2025 Warrants”).
   
(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) under the Securities Act, based on the average of the high and low prices of the shares of Common Stock as reported on The OTC QB Market on September 29, 2025.